Caribou Biosciences (CRBU) Cash from Operations (2020 - 2026)
Caribou Biosciences (CRBU) reported Cash from Operations of 27000000.0 for Q1 2026, up 26.48% year-over-year from 21347147.47 in Q1 2025, and down 29.61% on a QoQ basis from 20832000.0 in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Cash from Operations data on file, last reported at 27000000.0 in Q1 2026.
- Quarterly Cash from Operations rose 26.48% year-over-year to 27000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 101275000.0 (up 26.46% YoY) and the FY2025 annual result came in at 111000000.0, up 19.68% from the prior year.
- Cash from Operations retreated to 27000000.0 in Q1 2026 per CRBU's latest filing, from 20832000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 15185000.0 in Q2 2023 and bottomed at 37203000.0 in Q1 2024.
- The 5-year median for Cash from Operations is 27000000.0 (2026), against an average of 27085705.88.
- The widest annual swing landed in 2022, when Cash from Operations sank 206.7%; it then soared 41.27% in 2025.
- Tracing CRBU's Cash from Operations over 5 years: stood at 25044000.0 in 2022, then climbed by 14.63% to 21379000.0 in 2023, then plunged by 65.91% to 35470000.0 in 2024, then soared by 41.27% to 20832000.0 in 2025, then fell by 29.61% to 27000000.0 in 2026.
- Per Business Quant, the three latest CRBU Cash from Operations figures stand at 27000000.0 (Q1 2026), 20832000.0 (Q4 2025), and 25185000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -27.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.00 Mn |
| Mar 31, 2026 | -27.00 Mn |
| Dec 31, 2025 | -20.83 Mn |
| Dec 31, 2025 | -20.83 Mn |
| Sep 30, 2025 | -25.19 Mn |
| Sep 30, 2025 | -25.19 Mn |
| Jun 30, 2025 | -28.26 Mn |
| Jun 30, 2025 | -28.26 Mn |
| Mar 31, 2025 | -36.73 Mn |
| Mar 31, 2025 | -36.73 Mn |
| Dec 31, 2024 | -35.47 Mn |
| Dec 31, 2024 | -35.47 Mn |
| Sep 30, 2024 | -32.66 Mn |
| Sep 30, 2024 | -32.66 Mn |
| Jun 30, 2024 | -32.87 Mn |
| Jun 30, 2024 | -32.87 Mn |
| Mar 31, 2024 | -37.20 Mn |
| Mar 31, 2024 | -37.20 Mn |
| Dec 31, 2023 | -21.38 Mn |
| Dec 31, 2023 | -21.38 Mn |
| Sep 30, 2023 | -28.79 Mn |
| Sep 30, 2023 | -28.79 Mn |
| Jun 30, 2023 | -15.19 Mn |
| Jun 30, 2023 | -15.19 Mn |
| Mar 31, 2023 | -27.94 Mn |
| Mar 31, 2023 | -27.94 Mn |
| Dec 31, 2022 | -25.04 Mn |
| Dec 31, 2022 | -25.04 Mn |
| Sep 30, 2022 | -22.38 Mn |
| Sep 30, 2022 | -22.38 Mn |
| Jun 30, 2022 | -21.87 Mn |
| Jun 30, 2022 | -21.87 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -21.39 Mn |
| Dec 31, 2021 | -21.39 Mn |
| Sep 30, 2021 | -14.97 Mn |
| Sep 30, 2021 | -14.97 Mn |
| Jun 30, 2021 | -16.48 Mn |
| Jun 30, 2021 | -16.48 Mn |
| Mar 31, 2021 | 20.31 Mn |
| Mar 31, 2021 | 20.31 Mn |
| Dec 31, 2020 | -8.08 Mn |
| Dec 31, 2020 | -8.08 Mn |
| Sep 30, 2020 | -8.69 Mn |
| Sep 30, 2020 | -8.69 Mn |